Novo Nordisk has achieved a significant milestone with the United Kingdom's regulatory approval of its oral semaglutide formulation, marketed as Wegovy. This development introduces a non-injectable alternative for individuals seeking treatment for obesity and related conditions, marking an important advancement in weight management therapies.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) officially sanctioned the Wegovy tablet, which incorporates semaglutide, a GLP-1 receptor agonist. This medication is now available for adults diagnosed with obesity (BMI of 30 kg/m² or higher) or those classified as overweight (BMI between 27 kg/m² and under 30 kg/m²) who also present with at least one weight-associated health issue. The treatment is designed to complement a lifestyle regimen that includes a reduced-calorie diet and increased physical activity, underscoring a holistic approach to weight management.
The MHRA's decision was largely influenced by compelling evidence from the Phase 3 OASIS 4 clinical trial. This study involved 307 adults suffering from obesity or being overweight, who also had at least one weight-related comorbidity, excluding those with diabetes. The trial demonstrated substantial efficacy: participants receiving 25 mg semaglutide tablets experienced an average weight loss of approximately 13.6% over 64 weeks, a stark contrast to the 2.4% observed in the placebo group. Furthermore, among participants who consistently adhered to the treatment, weight reduction reached about 16.6%, compared to 2.7% in the placebo cohort after the same duration. These findings highlight the oral medication's significant potential in aiding weight loss.
Regarding safety, the oral semaglutide exhibited a profile consistent with its injectable counterpart. The most frequently reported adverse events were gastrointestinal disturbances, such as nausea, vomiting, and diarrhea, affecting 74.0% of the oral semaglutide group versus 42.2% in the placebo group. Novo Nordisk reported these side effects were generally mild to moderate and temporary. The rate of treatment discontinuation due to adverse events was approximately 6.9%, which aligns with observations from studies on injectable semaglutide. This consistency reassures both prescribers and patients about the drug's predictable safety profile.
Novo Nordisk has indicated its intention to roll out the Wegovy pill commercially in selected markets during the latter half of 2026. The UK's approval follows similar authorizations from the U.S. Food and Drug Administration and the United Arab Emirates' Emirates Drug Establishment, positioning the MHRA as the third regulatory body to endorse this innovative weight-loss solution. This sequence of approvals underscores the global recognition of oral semaglutide as a valuable addition to the therapeutic landscape for managing obesity. At the time of this publication, Novo Nordisk shares (NVO) registered a 1.20% increase, trading at $43.32, reflecting positive market sentiment following these regulatory advancements.